KBC Group NV decreased its stake in Pfizer (NYSE:PFE) by 6.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,094,344 shares of the biopharmaceutical company’s stock after selling 202,224 shares during the quarter. Pfizer makes up 1.0% of KBC Group NV’s holdings, making the stock its 12th biggest position. KBC Group NV owned about 0.05% of Pfizer worth $112,077,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Americafirst Capital Management LLC acquired a new position in Pfizer during the third quarter worth about $127,000. Delphi Private Advisors LLC boosted its position in Pfizer by 84.3% during the fourth quarter. Delphi Private Advisors LLC now owns 3,499 shares of the biopharmaceutical company’s stock worth $127,000 after acquiring an additional 1,600 shares during the last quarter. Lipe & Dalton boosted its position in Pfizer by 6.9% during the second quarter. Lipe & Dalton now owns 4,626 shares of the biopharmaceutical company’s stock worth $155,000 after acquiring an additional 300 shares during the last quarter. Legacy Advisors LLC acquired a new position in Pfizer during the third quarter worth about $164,000. Finally, Oak Point Wealth Management acquired a new position in Pfizer during the fourth quarter worth about $165,000. Institutional investors and hedge funds own 71.33% of the company’s stock.

A number of equities analysts recently weighed in on the stock. Sanford C. Bernstein set a $43.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research report on Tuesday, January 30th. Goldman Sachs set a $36.00 price target on shares of Pfizer and gave the stock a “neutral” rating in a research report on Tuesday, January 30th. UBS set a $42.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research report on Wednesday, January 31st. BMO Capital Markets set a $39.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research report on Tuesday, January 30th. Finally, Zacks Investment Research upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $40.00 price target on the stock in a research report on Wednesday, April 11th. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and nine have given a buy rating to the stock. Pfizer presently has a consensus rating of “Hold” and an average price target of $39.20.

In other news, EVP Sally Susman sold 33,368 shares of the business’s stock in a transaction that occurred on Tuesday, February 27th. The shares were sold at an average price of $37.03, for a total value of $1,235,617.04. Following the sale, the executive vice president now directly owns 191,505 shares of the company’s stock, valued at approximately $7,091,430.15. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director W Don Cornwell sold 1,758 shares of the business’s stock in a transaction that occurred on Tuesday, February 27th. The shares were sold at an average price of $36.79, for a total transaction of $64,676.82. Following the completion of the sale, the director now directly owns 1,000 shares in the company, valued at $36,790. The disclosure for this sale can be found here. Insiders sold a total of 248,037 shares of company stock worth $9,064,785 over the last three months. Insiders own 0.06% of the company’s stock.

Pfizer stock opened at $37.00 on Friday. The company has a market capitalization of $218,351.08, a PE ratio of 13.96, a P/E/G ratio of 1.83 and a beta of 0.90. Pfizer has a 1 year low of $31.67 and a 1 year high of $39.43. The company has a current ratio of 1.35, a quick ratio of 1.10 and a debt-to-equity ratio of 0.47.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.56 by $0.06. The business had revenue of $13.70 billion for the quarter, compared to the consensus estimate of $13.67 billion. Pfizer had a net margin of 40.55% and a return on equity of 25.21%. The business’s revenue was up .6% on a year-over-year basis. During the same period in the previous year, the firm earned $0.47 EPS. research analysts forecast that Pfizer will post 2.96 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, June 1st. Stockholders of record on Friday, May 11th will be paid a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.68%. Pfizer’s dividend payout ratio (DPR) is 51.32%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.